Generex Biotechnology Corporation (NasdaqCM: GNBT; www.generex.com) today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010. Both were podium presentations given by Dr. Douglas Powell, Director of Immunobiology at Antigen Express.
At the Gene based Vaccines conference, the purpose of which was to analyze novel vaccine design and delivery methods in order to translate evidence into clinical success, the presentation Examining the different novel prime boost strategies and their applications for potential clinical use described the combined use of the Ii-Key hybrids developed at Antigen Express with DNA vaccines as a more potent means for stimulating immunity. This immunization strategy has potential application both for better prevention of infectious diseases, like influenza, as well as for the treatment of chronic viral infections (e.g., HIV) and malignancies.
The focus Dr. Powell's presentation at the Immunotherapeutics and Vaccine Summit, entitled Synthetic Peptide Vaccine for Pandemic Flu was on the Company's development of vaccines for influenza. Clinical trials have been conducted on synthetic Ii-Key-modified peptides that are applicable to both the H5N1 and the 2009 H1N1 swine flu strains. Synthetic vaccines offer clear advantages over traditional egg or cell culture-based vaccines in their design, manufacturing, and use. The Company is continuing its work toward developing synthetic vaccines for both pandemic and seasonal influenza strains.
Targeted gene therapy shuts down cancer cells' energy centers